[go: up one dir, main page]

WO2008005769A3 - Procédés d'inhibition de la réplication du vhc - Google Patents

Procédés d'inhibition de la réplication du vhc Download PDF

Info

Publication number
WO2008005769A3
WO2008005769A3 PCT/US2007/072234 US2007072234W WO2008005769A3 WO 2008005769 A3 WO2008005769 A3 WO 2008005769A3 US 2007072234 W US2007072234 W US 2007072234W WO 2008005769 A3 WO2008005769 A3 WO 2008005769A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hcv replication
inhibiting hcv
replication
directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/072234
Other languages
English (en)
Other versions
WO2008005769A2 (fr
Inventor
Cornelis A Rijnbrand
Franz Amorsolo
Haekyung Lee
Flossie Wong-Staal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusol Inc
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Publication of WO2008005769A2 publication Critical patent/WO2008005769A2/fr
Publication of WO2008005769A3 publication Critical patent/WO2008005769A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés permettant d'inhiber la réplication du virus de l'hépatite C (VHC) dans des cellules. L'invention concerne également des procédés destinés à identifier des composés qui inhibent une telle réplication et confèrent ou augmentent la résistance à une infection par le VHC.
PCT/US2007/072234 2006-06-30 2007-06-27 Procédés d'inhibition de la réplication du vhc Ceased WO2008005769A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80635406P 2006-06-30 2006-06-30
US60/806,354 2006-06-30

Publications (2)

Publication Number Publication Date
WO2008005769A2 WO2008005769A2 (fr) 2008-01-10
WO2008005769A3 true WO2008005769A3 (fr) 2008-12-04

Family

ID=38895326

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072234 Ceased WO2008005769A2 (fr) 2006-06-30 2007-06-27 Procédés d'inhibition de la réplication du vhc

Country Status (1)

Country Link
WO (1) WO2008005769A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US20070031844A1 (en) * 2002-11-14 2007-02-08 Anastasia Khvorova Functional and hyperfunctional siRNA

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US20070031844A1 (en) * 2002-11-14 2007-02-08 Anastasia Khvorova Functional and hyperfunctional siRNA

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELBASHIR S.M. ET AL.: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate", THE EMBO J., vol. 20, no. 23, 2001, pages 6877 - 6888, XP002225998 *

Also Published As

Publication number Publication date
WO2008005769A2 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2010075376A3 (fr) Composés antiviraux
WO2010144646A3 (fr) Composés antiviraux
WO2007092888A3 (fr) Inhibiteurs ns5b hcv
WO2008021745A3 (fr) Inhibiteurs de la pénétration du virus de l'hépatite c
WO2008008776A3 (fr) Inhibiteurs du virus de l'hépatite c
WO2008060927A3 (fr) Inhibiteurs du virus c de l'hépatite
WO2008057995A3 (fr) Inhibiteurs de protéase de vhc
MX2011010905A (es) Compuestos antivirales.
MX2009004943A (es) Inhibidores del virus de la hepatitis c.
IL196815A0 (en) Hepatitis c virus inhibitors
NO20090447L (no) Hepatittt C virusinhibitorer
WO2007008657A3 (fr) Inhibiteurs du virus de l'hepatite c
ZA201005700B (en) Hepatitis c virus inhibitors
WO2008133753A3 (fr) Composés antiviraux
WO2008051514A3 (fr) Inhibiteurs de la protéase ns3 du hcv
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
WO2009029384A3 (fr) Composés utilisés dans le traitement de l'hépatite c
WO2010149598A3 (fr) Compose antiviral heterocyclique
WO2008051637A3 (fr) Composés de pyridazinone
EP2099903A4 (fr) Polymérases modifiées et virus atténués et leurs procédés d'utilisation
WO2008005769A3 (fr) Procédés d'inhibition de la réplication du vhc
HUE026600T2 (hu) Készítmények és eljárások virális hepatitis kezelésére
WO2007059221A3 (fr) Variantes du virus de l'hepatite c
WO2008110771A3 (fr) Composition
IL193113A0 (en) Heterocyclic antiviral compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07799077

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07799077

Country of ref document: EP

Kind code of ref document: A2